Meeting
2024 ASCO Annual Meeting
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
Authors
Stephen Lam Chan
Department of Clinical Oncology, Prince of Wales Hospital, Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong SAR, China
Stephen Lam Chan , Bruno Sangro , Masatoshi Kudo , Joseph P. Erinjeri , Shukui Qin , Zhenggang Ren , Yasuaki Arai , Valeriy Vladimirovich Breder , Shi-Ming Lin , Jean-Marie Peron , Tien Quang Nguyen , Lunan Yan , Chang-Fang Chiu , Florinda A. Santos , Anil Veluvolu , Satheesh Chiradoni Thungappa , Claire Morgan , Kerry Parsons , Ioannis Xynos , Riccardo Lencioni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT03778957
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4122)
DOI
10.1200/JCO.2024.42.16_suppl.4122
Abstract #
4122
Poster Bd #
102
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma.
First Author: Masatoshi Kudo
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima
Poster
2023 ASCO Annual Meeting
A phase 1b study to evaluate the efficacy, safety, and pharmacokinetics of an investigational microbiome therapeutic, SER-155, in adults undergoing hematopoietic stem cell transplantation.
First Author: Doris M. Ponce
Poster
2023 ASCO Annual Meeting
Phase I/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma: Final results.
First Author: Houda Bahig